Wei Yu
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- Epigenetics and DNA Methylation 13
- Hedgehog Signaling Pathway Studies 6
- Renal and related cancers 5
- Oncology 25
- Cancer Immunotherapy and Biomarkers 11
- Co-authors
- Sharmila Shankar (13 shared papers)Rakesh K. Srivastava (12 shared papers)Yiming Ma (9 shared papers)Anju Shrivastava (4 shared papers)Raj Kumar Verma (3 shared papers)Jing Yan (15 shared papers)John R. Falck (3 shared papers)Jing Yang (3 shared papers)
- Journals
- Journal of Clinical Oncology (8 papers)Journal of Cellular and Molecular Medicine (5 papers)Scientific Reports (4 papers)Annals of Oncology (4 papers)Journal of Ethnopharmacology (4 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Wei Yu
129 papers receiving 2.7k citations
Wei Yu's Hit Papers
Peers
Comparison fields: 5 of 133
- Oncology 770
- Cancer Research 423
- Pharmacology 155
- Molecular Biology 1.1k
- Biochemistry 85
Countries citing papers authored by Wei Yu
This map shows the geographic impact of Wei Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Yu more than expected).
Fields of papers citing papers by Wei Yu
This network shows the impact of papers produced by Wei Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Yu. The network helps show where Wei Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 134 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 146 | |
| 2 | 2020 | 114 | |
| 3 | 2018 | 108 | |
| 4 | Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer Hit paper breakdown → | 2023 | 107 |
| 5 | 2018 | 90 | |
| 6 | 2013 | 82 | |
| 7 | 2010 | 78 | |
| 8 | 2012 | 73 | |
| 9 | 2020 | 67 | |
| 10 | 2016 | 65 | |
| 11 | 2016 | 65 | |
| 12 | 2014 | 64 | |
| 13 | 2017 | 61 | |
| 14 | 2020 | 59 | |
| 15 | 2015 | 59 | |
| 16 | 2018 | 54 | |
| 17 | 2003 | 53 | |
| 18 | 2018 | 50 | |
| 19 | 2019 | 47 | |
| 20 | 2021 | 43 |
About Wei Yu
Wei Yu is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Surgery and Cancer Research, having authored 134 papers that have together received 2.7k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (13 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer-related molecular mechanisms research (8 papers), Lung Cancer Treatments and Mutations (7 papers), Pharmacological Effects of Natural Compounds (6 papers), Hedgehog Signaling Pathway Studies (6 papers), Renal and related cancers (5 papers) and Ferroptosis and cancer prognosis (5 papers). The work is most often cited by research in Oncology (770 citations), Cancer Research (423 citations), Pharmacology (155 citations), Molecular Biology (1.1k citations) and Biochemistry (85 citations). Wei Yu has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Sharmila Shankar, Rakesh K. Srivastava, Yiming Ma, Anju Shrivastava, Raj Kumar Verma, Jing Yan, John R. Falck, Jing Yang, Achim Rittmeyer and Christina Matheny. Their work appears in journals such as Journal of Clinical Oncology, Journal of Cellular and Molecular Medicine, Scientific Reports, Annals of Oncology and Journal of Ethnopharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.